Sentence examples for most trials comparing from inspiring English sources
Most trials comparing the preventive effect of CHX varnish were conducted on school children, adolescent or adults.
38, 39 Additionally, most trials comparing gonadotropins do not report on cumulative live-birth rates per treatment program, embryo quality, or dropout rates in subsequent frozen cycles.
In line with our own results, most trials comparing a DPP-4 inhibitor with SU, in combination with metformin, demonstrate a slightly higher risk of hypoglycaemia in the latter group [ 15- 18].
Most trials comparing heparin to citrate in CVVH had small numbers of patients and mainly focused on filter survival [ 10– 13], and only two had mortality as an outcome measure [ 14, 15].
18 19 20 To date, most trials comparing combination therapy with aliskiren and renin-angiotensin system blockers have focused on surrogate outcomes and have been underpowered to provide robust estimates of adverse events.
15, 17, 18, 21– 23 Most trials compare dulaglutide to placebo in addition to first-line metformin therapy and have demonstrated promising A1c reductions for dulaglutide.
Moreover, the most recent trials comparing PCI with CABG failed to provide a clear superiority.
Moreover, diagnostic angiography preceded randomisation in most strategy trials comparing revascularisation with medical treatment, which is likely to have resulted in the exclusion of higher risk patients.
In most pivotal trials comparing the effects of alendronate, 1 4 risedronate 5 7 or ibandronate 8 versus placebo, hip fractures were considered as secondary endpoints and outcomes did not show any clear potential benefit in decreasing hip-fracture risk.
74 An important fact to consider to truly appreciate the content of this recommendation, however, is that in most clinical trials comparing combination therapy with monotherapy head to head, GCs were either mandatory in the combination therapy arm or GC use was different between both arms, which probably explains the superiority of combination therapy.
Indeed, in most of the trials comparing IDeg/IDegAsp with a comparator arm, the incidence of cardiovascular events was estimated according to composite criteria of MACE (major adverse cardiovascular events) and MACE+.
